Latest Headlines

Latest Headlines

Top 10 best-selling cancer drugs of 2013

When it comes to selling big, cancer drugs have a lot going for them. Their targets--deadly diseases that in many cases can kill quickly--put them in high demand, even as they continue to redefine...

Merck KGaA eyes KRAS-gene focus to boost Erbitux sales

In an interview with  Reuters, Belén Garijo, head of the company's pharma unit Merck Serono, outlined a strategy for Erbitux centered on the KRAS mutation-free subgroup, which accounts for about 60% of all cases.

Oncobiologics allies with inVentiv on biosimilars development

The Cranbury, NJ-based biotech says they will focus on knockoffs of Humira, Rituxan, Avastin, Herceptin and Erbitux.

Bristol-Myers dumps rights to Lilly's troubled PhIII Erbitux successor

Three years after Bristol-Myers Squibb and Eli Lilly settled a nasty legal scrap over the rights to necitumumab--a cancer drug initially pursued by ImClone and pushed ahead into late-stage tests--BMS has dumped its rights to the troubled program.

Merck KGaA sees job cuts, price hikes pay off in Q3

Merck KGaA is already seeing the payoff from cost cuts. The German drugmaker beat expectations on third-quarter earnings, thanks in part to lower costs. Higher drug prices helped, too. In fact, the company raised its outlook for the year because of increased demand for its drugs, Bloomberg reports.

Drugmakers offer Greece option to end bad debt spiral

Drug companies are offering to take a haircut this year on what Greek hospitals owe them if the government will pay the debt and stop its healthcare facilities from running up more unpaid drug bills.

Merck yanks European app for Erbitux in lung cancer

Merck KGaA has hit another obstacle on its path to expanding Erbitux sales. The German drugmaker pulled its marketing application for a non-small cell lung cancer use in Europe--for the second time.

Merck KGaA grabs a cancer antibody hybrid in $625M Symphogen pact

Danish biotech Symphogen picked up a major league pharma partner today along with an injection of fresh cash. Merck KGaA snagged Symphogen's second program--an anti-EGFR "mixed" antibody now in Phase II--with a €20 million ($25 million) upfront payment and promises of up to €475 million ($600 million) more in development and commercial milestones.

Avastin tops list of most-requested cancer meds in U.K.

When U.K. doctors request special funding for cancer drugs, which product do they request most often? That would be Roche's ($RHHBY) Avastin, hands down. Of the more than 10,000 petitions to the cancer drugs fund from April 2011 to March 2012, almost 25% were for Avastin.

FDA approves Sanofi's Zaltrap for colorectal cancer

Though Zaltrap isn't expected to be a blockbuster, Sanofi's approval bolsters the Paris-based pharma giant's mission to usher new drugs to market as its major sellers such as the blood thinner Plavix face generic drug competition.